Neostigmine
نئوستیگمین
🧠 Nervous SystemCholinesterase inhibitor
Market / country: 🇺🇸 USA
Bloxiverz (US)
🧮 Dose calculator
Reversal of neuromuscular blockade · Regimen source: FDA Neostigmine · 2.2
- • Only when the first TOF twitch is at least 10% of baseline. Atropine or glycopyrrolate before or with it (separate syringe). Children dosed as adults. FDA Neostigmine · 2.2FDA Neostigmine · 2.4FDA Neostigmine · 2.3
Enter age and weight.
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity to neostigmine; peritonitis or mechanical obstruction of the intestinal or urinary tract. FDA Neostigmine · 4
Warnings
- • Bradycardia, bronchospasm; maximum total 0.07 mg/kg or 5 mg (whichever is less). FDA Neostigmine · 5FDA Neostigmine · 2.2
Formulations
- 0.5 mg/mL (10 mL vial) — injection 🇺🇸 USA FDA Neostigmine · 3
- 1 mg/mL (10 mL vial) — injection 🇺🇸 USA FDA Neostigmine · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Neostigmine · 8.1
“Risk Summary There are no adequate or well-controlled studies of neostigmine methylsulfate injection in pregnant women.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Neostigmine · 8.2
“Risk summary Neostigmine methylsulfate has not been studied in lactating women.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Neostigmine · 8.4
“Neostigmine methylsulfate injection is approved for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery in pediatric patients of all ages.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Neostigmine · 8.5
“Because elderly patients are more likely to have decreased renal function, neostigmine methylsulfate injection should be used with caution and monitored for a longer period in elderly patients.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA208405
- DailyMed (FDA label)FDA Neostigmine
- MedlinePlus (NIH)❌ None
- WHO ATC/DDDN07AA01
- Darooyab (Iran)Neostigmine
🇮🇷 Registered in Iran Darooyab · G-3049/Neostigmine
Dosage forms with Iranian generic codes, per Darooyab.
- 01817 · NEOSTIGMINE BROMIDE 15MG TAB · قرص نئوستیگمین بروماید ۱۵ میلیگرم
- 00893 · NEOSTIGMINE METHYLSULFATE 0.5MG/1ML AMP · آمپول نئوستیگمین متیلسولفات ۰٫۵ میلیگرم / ۱ میلیلیتر
- 00894 · NEOSTIGMINE METHYLSULFATE 12.5MG/5ML AMP · آمپول نئوستیگمین متیلسولفات ۱۲٫۵ میلیگرم / ۵ میلیلیتر
- 00895 · NEOSTIGMINE METHYLSULFATE 2.5MG/1ML AMP · آمپول نئوستیگمین متیلسولفات ۲٫۵ میلیگرم / ۱ میلیلیتر
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Neostigmine · 3FDA Neostigmine · 2.2FDA Neostigmine · 2.4FDA Neostigmine · 2.3FDA Neostigmine · 4FDA Neostigmine · 5FDA Neostigmine · SPL approval / marketing categoryFDA Neostigmine · 8.1FDA Neostigmine · 8.2FDA Neostigmine · 8.4FDA Neostigmine · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-3049/Neostigmine
- Clinical review⚠ Unverified